{"id":"daprodustat-small","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Thromboembolic events"}]},"_chembl":{"chemblId":"CHEMBL3544988","moleculeType":"Small molecule","molecularWeight":"393.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting prolyl hydroxylase enzymes, daprodustat prevents the degradation of hypoxia-inducible factor (HIF), allowing HIF to accumulate and activate genes involved in erythropoietin (EPO) synthesis. This mimics the body's natural response to low oxygen and stimulates erythropoiesis without requiring exogenous EPO injections. The mechanism is particularly useful in chronic kidney disease where EPO production is impaired.","oneSentence":"Daprodustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that stabilizes HIF to increase endogenous erythropoietin production and boost red blood cell formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:35.627Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia of chronic kidney disease in patients not on dialysis"},{"name":"Anemia of chronic kidney disease in patients on dialysis"}]},"trialDetails":[{"nctId":"NCT03446612","phase":"PHASE2","title":"Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-01-10","conditions":"Anaemia","enrollment":6},{"nctId":"NCT02969655","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-11-21","conditions":"Anaemia","enrollment":271}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Daprodustat small","genericName":"Daprodustat small","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daprodustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that stabilizes HIF to increase endogenous erythropoietin production and boost red blood cell formation. Used for Anemia of chronic kidney disease in patients not on dialysis, Anemia of chronic kidney disease in patients on dialysis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}